内容紹介
Effect of Pegfilgrastim Primary Prophylactic Administration on Relative Dose Intensity(RDI)in Postoperative Adjuvant Chemotherapy(TC Therapy)for Breast Cancer―A Single-Center, Retrospective Study
Summary
This study assessed the effect of pegfilgrastim in patients with early stage breast cancer who were receiving docetaxel and cyclophosphamide(TC)therapy(75 mg/m2 docetaxel plus 600 mg/m2 cyclophosphamide). In total, 17 patients who were to receive 4 planned cycles of TC therapy every 3 weeks were included in this study. Of the 17 patients, 10 who received pegfilgrastim after January 2016 formed the Peg-G group and 7 who did not receive pegfilgrastim until December 2015 formed the control group. We observed a high successful execution rate and relative dose intensity(RDI)with docetaxel in both groups. The successful execution rates were 100% in the Peg-G group and 42.8% in the control group. The RDI was 86.5%(65.4-100%)in the Peg-G group and 52.5%(48.0-58.0%)in the control group. This study showed that the use of pegfilgrastim results in a high successful execution rate and RDI in patients with early stage breast cancer undergoing TC therapy.
要旨
早期乳癌患者に対するTC療法(docetaxel 75 mg/m2,cyclophosphamide 600 mg/m2)のrelative dose intensity(RDI)を,pegfilgrastim一次予防的投与した症例とpegfilgrastimを投与していない症例に分け,比較検討した。対象はTC療法を3週ごとに4サイクルを予定した17例とした。2016年1月からの10例にはpegfilgrastimを一次予防的投与し(Peg-G群),2015年12月までのpegfilgrastimを使用していない7例(control群)に分けた。各群における4サイクル完遂率と,docetaxelのRDIを検討した。4サイクル完遂率は,Peg-G群は100%,control群は42.8%であった。4サイクル完遂例のRDIは,Peg-G群86.5(65.4～100)%,control群52.5(48.0～58.0)%であった。TC療法においてはpegfilgrastim一次予防的投与することで,高い4サイクル完遂率とRDIが維持できることが示された。
目次
Summary
This study assessed the effect of pegfilgrastim in patients with early stage breast cancer who were receiving docetaxel and cyclophosphamide(TC)therapy(75 mg/m2 docetaxel plus 600 mg/m2 cyclophosphamide). In total, 17 patients who were to receive 4 planned cycles of TC therapy every 3 weeks were included in this study. Of the 17 patients, 10 who received pegfilgrastim after January 2016 formed the Peg-G group and 7 who did not receive pegfilgrastim until December 2015 formed the control group. We observed a high successful execution rate and relative dose intensity(RDI)with docetaxel in both groups. The successful execution rates were 100% in the Peg-G group and 42.8% in the control group. The RDI was 86.5%(65.4-100%)in the Peg-G group and 52.5%(48.0-58.0%)in the control group. This study showed that the use of pegfilgrastim results in a high successful execution rate and RDI in patients with early stage breast cancer undergoing TC therapy.
要旨
早期乳癌患者に対するTC療法(docetaxel 75 mg/m2,cyclophosphamide 600 mg/m2)のrelative dose intensity(RDI)を,pegfilgrastim一次予防的投与した症例とpegfilgrastimを投与していない症例に分け,比較検討した。対象はTC療法を3週ごとに4サイクルを予定した17例とした。2016年1月からの10例にはpegfilgrastimを一次予防的投与し(Peg-G群),2015年12月までのpegfilgrastimを使用していない7例(control群)に分けた。各群における4サイクル完遂率と,docetaxelのRDIを検討した。4サイクル完遂率は,Peg-G群は100%,control群は42.8%であった。4サイクル完遂例のRDIは,Peg-G群86.5(65.4～100)%,control群52.5(48.0～58.0)%であった。TC療法においてはpegfilgrastim一次予防的投与することで,高い4サイクル完遂率とRDIが維持できることが示された。